The Department of Health's adoption of the generic drug Risdiplam for spinal muscular atrophy significantly enhances patient access, reducing costs from ₹6.2 lakh to ₹15,900 per bottle. This policy change is crucial for improving the quality of life for patients with this life-threatening genetic disorder.
The Department of Health's adoption of affordable generic Risdiplam for Spinal Muscular Atrophy marks a major victory for patient access and public health Spinal Muscular Atrophy (SMA) is a rare, life-threatening genetic disorder that progressively weakens muscles, severely impairing both mobility and respiratory function. Although a complete cure remains elusive, Risdiplam is currently available as a pharmaceutical intervention capable of significantly decelerating disease progression. Timely administration of this medication is critical for enhancing patients’ quality of life and longevity. Roche’s branded therapeutic equivalent, Evrysdi (Risdiplam), costs about ₹6.2 lakh per bottle. Conversely, Natco’s generic version costs only ₹15,900 per bottle. Since a single bottle typically lasts 12 days, Natco’s monthly expenditure is about ₹30,000 (though actual costs may vary based on the patient’s age, dosage, and volume used). The availability of scientifically validated, universally recognised generic pharmaceuticals at lower cost is a major benefit for SMA patients and their families. Consequently, the Department of Health must disregard these unfounded media campaigns and steadfastly advance this decisive, patient-centric initiative. Dr B Ekbal is a former professor of neurosurgery and a public health activist. When authorised enterprises such as Natco introduce generic formulations, they must legally and scientifically demonstrate bioequivalence, proving that the drug enters the bloodstream in a manner comparable to the branded original. Under the Drugs and Cosmetics Act, regulatory approval for any generic pharmaceutical is granted only after successful completion of rigorous bioequivalence studies.
Original title: “Why recognising a generic drug for Spinal Muscular Atrophy is significant - The Week”